Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors

Trial Profile

Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Onalespib (Primary) ; Dabrafenib; Trametinib
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018.
    • 12 Apr 2016 Status changed from suspended to recruiting.
    • 03 Feb 2016 Status changed from recruiting to suspended as CTEP Initiated Action.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top